Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Close Caregiver Relationship May Slow Alzheimer's Decline
A study led by Johns Hopkins and Utah State University researchers suggests that a particularly close relationship with caregivers may give people with Alzheimer"s disease a marked edge over those without one in retaining mind and brain function over time. The beneficial effect of emotional intimacy that the researchers saw among participants was on par with some drugs used to treat the disease.
generic viagra online
Uganda To Distribute ITNs To All Citizens
The Ugandan ministry of health said that everyone in the country will receive free insecticide-treated nets (ITNs) to prevent malaria beginning in September, James Kakooza, the state minister for primary health care, said, New Vision/allAfrica.com reports. Kakooza said children and mothers will be the priority, but that the goal is to make the 17.4 million imported ITNs available to everyone. The ITNs will supplement 6 million ITNs that were distributed over the last three years, Richard Ndyomugyenyi, the malaria control program officer, said.
News of the day
Lexicon Initiates Phase 2 Clinical Trial Of LX1032 In Patients With Carcinoid Syndrome
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company"s oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.
Endocrinology

Protalix Holds Pre-NDA Meeting With FDA For PrGCD For The Treatment Of Gaucher Disease

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced that the Company held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to discuss the a proposed new drug application (NDA) submission for prGCD, a new proprietary plant-cell expressed recombinant form of glucocerebrosidase, for the treatment of Gaucher disease and to confirm the clinical, nonclinical and chemistry requirements for the proposed NDA filing. prGCD is currently the subject of a pivotal Phase III clinical trial being conducted under the FDA"s Special Protocol Assessment (SPA) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans with severe and debilitating symptoms. "This meeting gives us confidence that we will be able to submit the NDA as planned and brings us one step closer to our goal of making prGCD commercially available to Gaucher disease patients through their treating physicians," said Dr. David Aviezer, President and Chief Executive Officer. "We look forward to announcing the results of our ongoing pivotal Phase III clinical trial for prGCD in the fourth quarter of 2009 and anticipate submitting the NDA before the end of the year." Protalix BioTherapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009